Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LGMN | Q99538 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2612165 | 0.86 | HPGD (0.55) | HPGDMAPTALDH1A1KDM4ELGMN | |
| SCHEMBL23536170 | 0.78 | KDM4E (0.57) | HPGDMAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL29948600 | 0.78 | KDM4E (0.57) | HPGDMAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL3436315 | 0.76 | ALDH1A1 (0.64) | HPGDMAPTALDH1A1KDM4ELGMN | |
| SCHEMBL2165481 | 0.76 | ALDH1A1 (0.67) | HPGDMAPTALDH1A1KDM4ELGMN | |
| SCHEMBL2608433 | 0.76 | NPC1 (0.50) | MAPTALDH1A1KMT2AMEN1CYP2C19 | |
| SCHEMBL31458523 | 0.76 | TSHR (0.60) | HPGDMAPTALDH1A1KDM4ELGMN | |
| SCHEMBL2080093 | 0.74 | LGMN (0.71) | HPGDMAPTALDH1A1KDM4ELGMN | |
| SCHEMBL196131 | 0.74 | HPGD (0.61) | HPGDMAPTALDH1A1KDM4ELGMN | |
| SCHEMBL14804207 | 0.74 | HPGD (0.61) | HPGDMAPTALDH1A1KDM4ELGMN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610317-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160082069-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9233136-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140328796-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8785378-B2 | Macrocyclic peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8445430-B2 | Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus | ACHILLION PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8163693-B2 | Urea-containing peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110070168-A1 | MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7906619-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100124545-A1 | CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20090082261-A1 | UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090048297-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070168-A1 | MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, ZC3HAV1L | HPGD 3204/4885MAPT 4655/4885ALDH1A1 4490/4885 |
| US-20090082261-A1 | UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, SLC14A1, RPL35 | HPGD 3897/4885MAPT 1638/4885ALDH1A1 4465/4885 |
| US-20160082069-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ZC3HAV1, VIP, ZC3HAV1L | HPGD 3279/4885MAPT 4060/4885ALDH1A1 3885/4885 |
| US-20140328796-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, CCL5 | HPGD 4148/4885MAPT 4499/4885ALDH1A1 4010/4885 |
| US-20090048297-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, CCL5 | HPGD 4148/4885MAPT 4499/4885ALDH1A1 4010/4885 |
| US-20100124545-A1 | CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS | CPS1, CCKAR, C1R | HPGD 2592/4885MAPT 4530/4885ALDH1A1 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.